Figure 5.
Cumulative incidence of cardiovascular death, myocardial infarction, and ischemic stroke by risk stratification and treatment group in women and men. Each risk indicator (ie, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, prior coronary artery bypass grafting, peripheral arterial disease, estimated glomerular filtration rate <60 ml/min/1.73 m2, and current smoking) is assigned 1 point. Low risk, 0 or 1 risk indicator; intermediate risk, 2 risk indicators; and high risk, ≧3 risk indicators. Women categorized as high risk benefitted the most from adding ezetimibe to simvastatin, whereas no benefit was observed in women who were categorized as low risk. Eze indicates ezetimibe; HR, hazard ratio; PBO, placebo; Simva, simvastatin.